Pharmacological protection of the gonads

Medical and Pediatric Oncology

Volumn 33, Issue 1, 1999, Pages 41-45

  Howell, S J ^a   Shalet, S M ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; LOMUSTINE; MELPHALAN; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCA ALKALOID;

AZOOSPERMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL PROTECTION; CONFERENCE PAPER; CRYOPRESERVATION; CYTOTOXICITY; FEMALE; GERM CELL; GONAD DOSE; HODGKIN DISEASE; HUMAN; MALE; OVARY FUNCTION; PRIORITY JOURNAL; RADIATION STERILIZATION; SPERMATOGENESIS; TESTIS CANCER; TESTIS DISEASE;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; CHILD; CRYOPRESERVATION; FEMALE; HUMANS; INFERTILITY; MALE; NEOPLASMS; OVARY; RADIATION INJURIES; SEMEN PRESERVATION; SURVIVORS; TESTIS;

EID: 0033023383     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199907)33:1<41::AID-MPO8>3.0.CO;2-I     Document Type: Conference Paper

References (48)

1. Spitz S. The histological effects of nitrogen mustard on human tumours and tissues. Cancer 1948;1:383-398.
2. Chapman RM, Sutcliffe SB, Rees LH, et al. Cyclical combination chemotherapy and gonadal function. Retrospective study in males. Lancet 1979;1:285-289.
3. Whitehead E, Shalet SM, Blackledge G, et al. The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male. Cancer 1982;49:418-4122.
4. Charak BS, Gupta R, Mandrekar P, et al. Testicular dysfunction after cyclophosphamide-vincristine-procarbazine-prednisolone chemotherapy for advanced Hodgkin's disease. A long-term follow-up study. Cancer 1990;65:1903-1906.
5. Viviani S, Ragni G, Santoro A, et al. Testicular dysfunction in Hodgkin's disease before and after treatment. Eur J Cancer 1991; 27:1389-1392.
6. Chatterjee R, Mills W, Katz M, et al. Germ cell failure and Leydig cell insufficiency in post-pubertal males after autologous bone marrow transplantation with BEAM for lymphoma. Bone Marrow Transplant 1994;13:519-522.
7. Mackie EJ, Radford M, Shalet SM. Gonadal function following chemotherapy for childhood Hodgkin's disease. Med Pediatr Oncol 1996;27:74-78.
8. Viviani S, Santoro A, Ragni G, et al. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs. ABVD. Eur J Cancer Clin Oncol 1985;21:601-605.
9. Hansen SW, Berthelsen JG, von der Maase H. Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J Clin Oncol 1990;8:1695-1698.
10. Stuart NS, Woodroffe CM, Grundy R, Cullen MH. Long-term toxicity of chemotherapy for testicular cancer-the cost of cure. Br J Cancer 1990;61:479-484.
11. Lampe H, Horwich A, Norman A, et al. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 1997;15: 239-245.
12. Palmieri G, Lotrecchiano G, Ricci G, et al. Gonadal function after multimodality treatment in men with testicular germ cell cancer. Eur J Endocrinol 1996;134:431-436.
13. Whitehead E, Shalet SM, Blackledge G, et al. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer 1983;52:988-993.
14. Bokemeyer C, Schmoll HJ, van Rhee J, et al. Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. Ann Hematol 1994;68:105-110.
15. Kreuser ED, Xiros N, Hetzel WD, Heimpel H. Reproductive and endocrine gonadal capacity in patients treated with COPP chemotherapy for Hodgkin's disease. J Cancer Res Clin Oncol 1987; 113:260-266.
16. Royere D, Barthelemy C, Hamamah S, Lansac J. Cryopreservation of spermatozoa: A 1996 review. Hum Reprod Update 1996; 2:553-559.
17. Mulhall JP, Burgess CM, Cunningham D, et al. Presence of mature sperm in testicular parenchyma of men with nonobstructive azoospermia: prevalence and predictive factors. Urology 1997;49: 91-95.
18. Chapman RM, Sutcliffe SB, Malpas JS. Male gonadal dysfunction in Hodgkin's disease. A prospective study. JAMA 1981;245: 1323-1328.
19. Padron OF, Sharma RK, Thomas AJ Jr, Agarwal A. Effects of cancer on spermatozoa quality after cryopreservation: A 12-year experience. Fertil Steril 1997;67:326-331.
20. Aboulghar MA, Mansour RT, Serour GI, et al. Fertilization and pregnancy rates after intracytoplasmic sperm injection using ejaculate semen and surgically retrieved sperm. Fertil Steril 1997; 68:108-111.
21. Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA 1988;259: 2123-2125.
22. Ward JA, Robinson J, Furr BJ, et al. Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist. Cancer Res 1990;50:568-574.
23. Delic JI, Bush C, Peckham MJ. Protection from procarbazine-induced damage of spermatogenesis in the rat by androgen. Cancer Res 1986;46:1909-1914.
24. Kurdoglu B, Wilson G, Parchuri N, et al. Protection from radiation-induced damage to spermatogenesis by hormone treatment. Radiat Res 1994;139:97-102.
25. Pogach LM, Lee Y, Gould S, et al. Partial prevention of procarbazine induced germinal cell aplasia in rats by sequential GnRH antagonist and testosterone administration. Cancer Res 1988;48: 4354-4360.
26. Meistrich ML, Parchuri N, Wilson G, et al. Hormonal protection from cyclophosphamide-induced inactivation of rat stem spermatogonia. J Androl 1995;16:334-341.
27. Kangasniemi M, Wilson G, Huhtaniemi I, Meistrich ML. Protection against procarbazine-induced testicular damage by GnRH-agonist and antiandrogen treatment in the rat. Endocrinology 1995;136:3677-3680.
28. Meistrich ML, Kangasniemi M. Hormone treatment after irradiation stimulates recovery of rat spermatogenesis from surviving spermatogonia. J Androl 1997;18:80-87.
29. Johnson DH, Linde R, Hainsworth JD, et al. Effect of a luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: Preliminary observations. Blood 1985;65:832-836.
30. Waxman JH, Ahmed R, Smith D, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol 1987;19:159-162.
31. Kreuser ED, Hetzel WD, Hautmann R, Pfeiffer EF. Reproductive toxicity with and without LHRHA administration during adjuvant chemotherapy in patients with germ cell tumors. Horm Metab Res 1990;22:494-498.
32. Brennemann W, Brensing KA, Leipner N, et al. Attempted protection of spermatogenesis from irradiation in patients with seminoma by D-tryptophan-6 luteinizing hormone releasing hormone. Clin Invest 1994;72:838-842.
33. Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin's disease in childhood: The Stanford experience [see comments]. Int J Radiat Oncol Biol Phys 1990;19:873-880.
34. Das PK, Das BK, Sahu DC, et al. Male gonadal function in Hodgkin's disease before and after treatment. J Assoc Physicians India 1994;42:604-605.
35. Giwercman A, von der Maase H, Berthelsen JG, et al. Localized irradiation of testes with carcinoma in situ: effects on Leydig cell function and eradication of malignant germ cells in 20 patients. J Clin Endocrinol Metab 1991;73:596-603.
36. Brinster RL, Zimmermann JW. Spermatogenesis following male germ-cell transplantation [see comments], Proc Natl Acad Sci USA 1994;91:11298-11302.
37. Haie Meder C, Mlika Cabanne N, Michel G, el al. Radiotherapy after ovarian transposition: ovarian function and fertility preservation [see commenls]. Int J Radial Oncol Biol Phys 1993;25: 419-424.
38. Ray GR, Trueblood HW, Enright LP, et al. Oophoropexy: A means of preserving ovarian function following pelvic megavoltage radiotherapy for Hodgkin's disease. Radiology 1970;96:175-180.
39. Bokser L, Szende B, Schally AV. Protective effects of D-Trp6-luteinising hormone-releasing hormone microcapsules against cyclophosphamide-induced gonadotoxicity in female rats. Br J Cancer 1990;61:861-865.
40. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995; 52:365-372.
41. Blumenfeld Z, Avivi I, Linn S, et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996;11:1620-1626.
42. Gosden RG, Baird DT, Wade JC, Webb R. Restoration of fertility to oophorectornized sheep by ovarian autografts stored at -196°C. Hum Reprod 1994;9:597-603.
43. Newton H, Aubard Y, Rutherford A, et al. Low temperature storage and grafting of human ovarian tissue. Hum Reprod 1996;11: 1487-1491.
44. Hovatta O, Silye R, Krausz T, et al. Cryopreservation of human ovarian tissue using dimethylsulphoxide and propanediol-sucrose as cryoprotectants. Hum Reprod 1996;11:1268-1272.
45. Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996;87:3045-3052.
46. Clayton PE, Shalet SM, Price DA, Campbell RH. Testicular damage after chemotherapy for childhood brain tumors. J Pediatr 1988;112:922-926.
47. Vilar O. Effect of cytostatic drugs on human testicular function. In: Mancini RE, Martini L, editors. Male fertility and sterility. London: Academic Press, 1974. p 423-440.
48. Wallace WH, Shalet SM, Crowne EC, et al. Gonadal dysfunction due to cis-platinum. Med Pediatr Oncol 1989;17:409-413.